Aurora Spine (ASG) Investor presentation summary

Company overview and market positioning

• Developed innovative, minimally invasive spinal implant technologies targeting both spine surgeons and pain interventionalists, with a focus on making procedures easier and more effective for doctors and patients.

• Headquartered in Carlsbad, CA, with 32 full-time employees and a growing presence in the larger pain/interventional market.

• Mission centers on patient well-being, offering implants that match patient anatomy and prioritizing less invasive solutions.

• Entered the pain management market in 2020, addressing a significant need as over 30 million Americans suffer from lower back pain.

Recent accomplishments and growth initiatives

• Launched Hydra AiRO Facet Fusion System (FDA cleared March 2025), expanded internal sales team, and introduced a branded line of biologics.

• Achieved record revenues and strong gross margins (~61%) for the first nine months of 2025, driven by proprietary products and internal sales.

• Continued EBITDAC improvement, with 9M 2025 EBITDAC positive and better than FY24.

• Quality Management System is ISO 13485 MDSAP certified, enabling sales in major global markets.

Proprietary product platforms and innovation

• Multiple proprietary platforms: ZIP (lumbar), SILO/TFX (SI joint), DEXA-C/L (cervical/lumbar), Hydra AiRO (facet fusion), and Apollo (cervical plates).

• ZIP implant reduces OR time by 36%, hospital stay by 40%, and blood loss by 69% compared to pedicle screws.

• SILO TFX is the fastest-growing product, with revenues rising from $3.2M in 2022 to $8.2M TTM.

• DEXA technology matches implant stiffness to patient bone density, minimizing subsidence and supporting osseointegration.

• Launched a new biologics division in Q4 2025, offering a suite of allograft solutions to complement implants.